Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $21.8333.

Several equities research analysts recently weighed in on TBPH shares. Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. TD Cowen upped their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. BTIG Research reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. B. Riley Financial upped their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th.

Get Theravance Biopharma alerts:

View Our Latest Stock Report on Theravance Biopharma

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Theravance Biopharma in the third quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the period. CIBC Private Wealth Group LLC raised its position in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $16.64 on Friday. Theravance Biopharma has a 1 year low of $10.42 and a 1 year high of $21.03. The company has a market cap of $857.84 million, a price-to-earnings ratio of 7.56 and a beta of 0.17. The firm has a fifty day moving average of $16.46 and a 200-day moving average of $17.47.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The firm had revenue of $17.70 million for the quarter. Analysts predict that Theravance Biopharma will post 1.54 EPS for the current year.

Theravance Biopharma Company Profile

(Get Free Report)

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

Read More

• Five stocks we like better than Theravance Biopharma
• Time to Sell? 3 Winners With Fading Technical Momentum
• Why These 2 Hotel Stocks Are Beating Travel Peers
• This Energy Stock Has Quietly Soared 130% in a Year
• 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.